Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Epilepsy D004827 35 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Escherichia coli Infections D004927 17 associated lipids
Extravasation of Diagnostic and Therapeutic Materials D005119 3 associated lipids
Fetal Growth Retardation D005317 9 associated lipids
Fever D005334 35 associated lipids
Fibrosis D005355 23 associated lipids
Gastritis D005756 27 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Glioma D005910 112 associated lipids
Gliosis D005911 6 associated lipids
Glomerulonephritis D005921 35 associated lipids
Glomerulonephritis, IGA D005922 7 associated lipids
Rhinitis, Allergic, Seasonal D006255 7 associated lipids
Heart Arrest D006323 13 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Cardiomegaly D006332 31 associated lipids
Heart Injuries D006335 6 associated lipids
Hematoma, Subdural D006408 3 associated lipids
Hemolysis D006461 131 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Eche N et al. Platelet aggregating and procoagulant activities of cultured human breast cancer cells (FAM). 1986 Thromb. Res. pmid:3726808
Kakishita E et al. Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood. 1990 Thromb. Res. pmid:2082481
Chang GT et al. Purification and characterization of a new anticoagulant protein, PP27, from placenta. 2005 Thromb. Res. pmid:16122555
Simon MF et al. Effect of BN 52021, a specific antagonist of platelet activating factor (PAF-acether), on calcium movements and phosphatidic acid production induced by PAF-acether in human platelets. 1987 Thromb. Res. pmid:3576518
Bochkov VN et al. LDL- and agonist-induced Ca(2+)-mobilization in platelets of healthy subjects and in patients with familial hyperlipoproteinemia type II. 1991 Thromb. Res. pmid:2063348
Alam I and Silver MJ Metabolism of 1-alkyl-2-acyl-GPC in human platelets in response to stimulation by thrombin. 1987 Thromb. Res. pmid:3576519
Filep JG et al. C-reactive protein inhibits binding of platelet-activating factor to human platelets. 1991 Thromb. Res. pmid:2063349
Slattery CW and Beaumont DO Sheep platelets as a model for human platelets: evidence for specific PAF (platelet activating factor) receptors. 1989 Thromb. Res. pmid:2554526
Liu X et al. Ginkgolide B inhibits platelet release by blocking Syk and p38 MAPK phosphorylation in thrombin-stimulated platelets. 2014 Thromb. Res. pmid:25223809
Hanss M and Dechavanne M 48740 RP, an antagonist of PAF, does not affect human plasma fibrinolysis before and after venous occlusion. 1988 Thromb. Res. pmid:3126559
Okamoto M et al. Platelet activating factor (PAF) involvement in endotoxin-induced thrombocytopenia in rabbits: studies with FR-900452, a specific inhibitor of PAF. 1986 Thromb. Res. pmid:3754990
Bretschneider E et al. ADP-, PAF- and adrenaline-induced platelet aggregation and thromboxane formation are not affected by a thromboxane receptor antagonist at physiological external Ca++ concentrations. 1994 Thromb. Res. pmid:7992234
Jones KP et al. Salivary PAF in acute myocardial infarction and angina: changes during hospital treatment and relationship to cardiac enzymes. 1994 Thromb. Res. pmid:7992251
Namm DH et al. Species specificity of the platelet responses to 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine. 1982 Thromb. Res. pmid:7071810
Juhan-Vague I et al. Possible participation of adenosine 5'-diphosphate, arachidonic acid and paf-acether in the platelet pro-aggregating effect of uncontrolled insulin-dependent diabetic erythrocytes in vitro. 1985 Thromb. Res. pmid:3923649
Kurose I et al. Involvement of superoxide anion and platelet-activating factor in increased tissue-type plasminogen activator during rat gastric microvascular damages. 1991 Thromb. Res. pmid:1650966
Westwick J et al. Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. 1986 Thromb. Res. pmid:3715810
Brown JE and Thuy LP The binding of bovine platelet aggregating factor to human platelets. 1981 Apr 1-15 Thromb. Res. pmid:7292446
Ishii H et al. Thiolprotease inhibitor, EST, can inhibit thrombin-induced platelet activation. 1990 Thromb. Res. pmid:2382255
Tokumura A et al. Platelet aggregation induced by ether-linked phospholipids. 1. Inhibitory actions of bovine serum albumin and structural analogues of platelet activating factor. 1987 Thromb. Res. pmid:3647677
Hofmann B et al. Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets. 1988 Thromb. Res. pmid:3381200
Davis RB and Johnson MF Effects of bacterial endotoxin and platelet activating factor (PAF) on human platelet aggregation in native whole blood. 1986 Thromb. Res. pmid:3544327
Heinrich J and Zimmermann RE Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. 1984 Thromb. Res. pmid:6523451
Hwang SB et al. Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. 1984 Thromb. Res. pmid:6429890
Skeaff CM and Holub BJ The effect of fish oil consumption on platelet aggregation responses in washed human platelet suspensions. 1988 Thromb. Res. pmid:3187952
Griffin KJ and Levy JV The thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF). 1988 Thromb. Res. pmid:3187959
Petty AC and Scrutton MC Platelet aggregation in whole blood: is the response to adrenaline, 5-hydroxytryptamine and PAF a direct consequence of stimulation by these agonists? 1989 Thromb. Res. pmid:2749609
Beaumont DO et al. Measuring platelet function with platelet shape change, an early event in aggregation. 1989 Thromb. Res. pmid:2646752
Janero DR et al. Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. 1988 Thromb. Res. pmid:3413730
Suttorp N et al. Stimulation of PAF-synthesis in pulmonary artery endothelial cells by Staphylococcus aureus alpha-toxin. 1992 Thromb. Res. pmid:1440526
Moon DG et al. Platelet activating factor and sheep platelets: a sensitive new bioassay. 1990 Thromb. Res. pmid:2326773
Violi F et al. Human platelet aggregation by PAF and thromboxane production. 1987 Thromb. Res. pmid:3424290
Benveniste J et al. Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. 1982 Thromb. Res. pmid:6803388
Seth P et al. Effect of platelet activating factor antagonists in different models of thrombosis. 1994 Thromb. Res. pmid:7900097
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Chlopicki S et al. Obligatory role of lipid mediators in platelet-neutrophil adhesion. 2003 Thromb. Res. pmid:14592550
Valone FH and Johnson B Decay of the activating signal after platelet stimulation with 1-0-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine: changes in calcium permeability. 1985 Thromb. Res. pmid:4082115
Kawamura M et al. Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation. 1993 Thromb. Res. pmid:8332959
Kohayakawa M and Inoue K Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. 1986 Thromb. Res. pmid:3083530
Stormorken H et al. A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). 1983 Thromb. Res. pmid:6857589
Kloprogge E et al. Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. 1983 Thromb. Res. pmid:6857605
Battistini B et al. Endothelin-1 does not affect human platelet aggregation in whole blood and platelet rich plasma. 1990 Thromb. Res. pmid:2278035
Leoncini G et al. Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. 1997 Thromb. Res. pmid:9175236
Despotis GJ et al. Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood. 1997 Thromb. Res. pmid:9175242
Hayashi M et al. Detection of platelet-activating factor in exudates of rats with phorbol myristate acetate-induced pleurisy. 1987 Thromb. Res. pmid:3433255
Avdonin PV et al. Blocking of the receptor-stimulated calcium entry into human platelets by verapamil and nicardipine. 1988 Thromb. Res. pmid:3232128
Lecompte T et al. Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP. 1990 Thromb. Res. pmid:2117306
Mabilat-Pragnon C et al. Urokinase localization and activity in isolated eosinophils. 1997 Thromb. Res. pmid:9526961
Kinlough-Rathbone RL et al. Effects of cathepsin G pretreatment of platelets on their subsequent responses to aggregating agents. 1999 Thromb. Res. pmid:10527409
Patterson WR et al. Aggregation of killer whale platelets. 1993 Thromb. Res. pmid:8327987